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enhancementAbstract Objective: Our objective is to ﬁnd out if the pattern of delayed myocardial enhancement
can be used as a key to diagnose and specify different types of cardiomyopathies.
Patients and methods: Fifty-four patients with suspected cardiomyopathy were enrolled in this
study. Patients’ age ranged from 3 to 68 years. All patients were subjected to history taking, labo-
ratory investigations, 2D echocardiography and cardiac magnetic resonance. Images were evaluated
for presence, distribution, pattern and site of delayed myocardial enhancement.
Results: Seven types of cardiomyopathies were diagnosed in this study. Each type had a character-
istic pattern of myocardial enhancement. Ischemic cardiomyopathy showed subendocardial up to
transmural enhancement within the territory of the coronary arteries. Dilated cardiomyopathy
showed midwall linear enhancement, hypertrophic cardiomyopathy showed patchy midwall
enhancement and restrictive cardiomyopathy showed subendocardial circumferential enhancement.
Arrythmogenic right ventricular dysplasia showed enhancement of the dilated right ventricle. Non-
compaction showed enhancement of the non-compacted area. Sarcoidosis showed midwall patchy
enhancement while Behcet’s disease showed right ventricular subendocardial enhancement.
Conclusion: The pattern of myocardial enhancement can be used as a key to diagnose all types of
cardiomyopathies. The use of cardiac magnetic resonance in cardiomyopathy is important to quan-
tify myocardial ﬁbrosis as this has prognostic implications.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Cardiomyopathy is deﬁned as myocardial disorder in which
there is structural and functional abnormality of the cardiac
muscle (1). Delayed contrast enhanced cardiac magnetic reso-
nance imaging has traditionally been used for the assessment
of infarction and viability in ischemic heart disease (2).
54 N.H. Behairy, S.M. MansourNon-ischemic cardiomyopathy presents a signiﬁcant diag-
nostic challenge, since initial symptoms are often vague and
overlapping with other disease entities (3). Determination of
the underlying cause of cardiomyopathy is essential in
deciding further diagnostic and therapeutic options, and
ultimately in determining prognosis. Echocardiography,
cardiac catheterization and nuclear scintigraphy have limited
roles in evaluation, as the appearances are non-speciﬁc.
Endomyocardial biopsy is not sensitive and hindered by
sampling error (3).
Cardiac magnetic resonance (CMR) allows a reproducible
and accurate evaluation of myocardial morphology, func-
tion, perfusion, and tissue damage in a non-invasive and
‘‘one-stop shop’’ way (4). Delayed contrast enhanced CMR
imaging is emerging as an increasingly useful modality for
the detection, characterization, and differentiation of cardio-
myopathies (2).
The objective of our study is to ﬁnd out if the pattern of de-
layed myocardial enhancement can be used as a key to diag-
nose and specify different types of cardiomyopathies.
2. Patients and methods
Fifty-four patients were enrolled in this study from May 2012
to June 2013. Patients were referred from the departments of
internal medicine, cardiology and pediatrics with suspected
cardiomyopathy based on clinical, echocardiography and
other investigation methods e.g. PET scan and coronary angi-
ography. Patients’ age ranged from 3 to 68 years with a mean
age of 35 years. Thirty-three patients were males and 21 fe-
males. All patients were subjected to history taking, routine
laboratory investigations, routine 2D echocardiography on
commercially available machines and cardiac magnetic reso-
nance (CMR). Patients with contraindication to CMR were
excluded; valve prosthesis, pace makers or general contraindi-
cations to MRI. The study was approved by the ethics commit-
tee in the Radiology department, Cairo University and
informed consents were obtained from all patients or their
guardians.
3. Echocardiography
Transthoracic echocardiography was performed on commer-
cially available ultrasound machines with a transducer of 2–
4 MHz. Routine short axis, 4- and 2-chamber views were ob-
tained in two to three cardiac cycles for the assessment of ejec-
tion fraction, stroke volume, ventricular and atrial dimensions,
wall thickness, segmental wall motion at apex, mid cavity and
base of both ventricle. Measurements were calculated by mod-
iﬁed Simpson’s rule.
4. Cardiac magnetic resonance
All patients were imaged by a 1.5 T super conducting magnet
(Gyroscan, Achieva Philips Medical Systems, Best the Nether-
lands) using a 16 channel phased-array cardiac coil with ECG
gating.
Patients were examined in supine position. All patients were
in sinus rhythm during the examination. Sedation was used for
children with oral chloral hydrate under supervision of an
anesthetic doctor.4.1. CMR protocol
The scan protocol was carried out in the following order: after
a survey and reference scan, steady state free precession
sequence with parallel imaging (balanced Fast Field Echo
(b-FFE) was acquired in 2-chamber, 4-chamber and multi-slice
short axis during single breath-holds (end expiratory of about
9–13 s) in 25 cardiac phases. TR/TE = 3.2/1.7, 215–256 · 256
matrix and 60 ﬂip angle with 320 mm FOV was performed for
all patients. In the short axis views; we used 8 mm slice thick-
ness and 10–12 slice numbers encompassing the ventricles.
Delayed myocardial enhancement scans were carried out in
short axis, 2-chamber and 4-chamber orientations 10–15 min
after IV injection of gadolinium (0.2 mm/kg) in adults and
after 5 min in the pediatric age group. IR TFE breath hold
with TR/TE = 6.1/3; ﬂip angle 25 and 8 mm slice thickness
was used. The inversion time was chosen by performing a T1
mapping using a look locker sequence in each patient to esti-
mate the proper inversion time which ranged from 200 to
320 ms. The evidence of delayed myocardial enhancement
was conﬁrmed by imaging different views of the myocardium.
4.2. LV functional analysis
LV global function was calculated by the Philips extended
work station (EWS) View Forum 2.6, after the manual tracing
of the endocardial and epicardial contours of the left ventricu-
lar wall at end diastole and end systole on the short axis cine
images. Wall thickness, wall motion abnormality, EDV,
ESV, CO, SV and EF were calculated.
4.3. Analysis and interpretation of late gadolinium enhancement
Segmental enhancement was quantiﬁed by the Philips extended
workstation (EWS) View Forum 2.6 in all 17 segments accord-
ing to the American heart association (AHA) classiﬁcation.
The presence of enhancement in each segment was scored by
visually assessing the area showing late gadolinium enhance-
ment as compared with the normal LV myocardium in each
segment. Images were evaluated for the presence, distribution,
pattern and site of delayed myocardial enhancement.
5. Results
We studied 54 patients with different types of cardiomyopa-
thies. Mean patient age was 35 years. According to the clinical,
echocardiographic and other investigatory ﬁndings seven dif-
ferent types of cardiomyopathies were diagnosed in this study
(Table 1). We divided the different types of cardiomyopathies
into two groups: ischemic and non-ischemic cardiomyopathies.
6. Ischemic cardiomyopathy
This group included 21 patients with known ischemic (acute
and chronic) cardiomyopathy diagnosed by laboratory,
clinical, coronary angiography and/or PET. All patients
(100%) showed delayed myocardial enhancement in the suben-
docardial region that extended to involve the whole myocar-
dial thickness (transmural enhancement) in some cases within
the territory of one or more coronary arteries (Fig. 1).
Table 1 Different types of cardiomyopathies included in this
study.











Total no of cases 54
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tion. LV functional analysis showed: hypokinesia up to akine-
sia in the involved cardiac segments with thinning of the wall
in chronic cases. Reduced CO and EF ranging from 35% to
55% were noted. LV thrombi were seen in ten cases, aneurys-
mal formation in three cases (Fig. 2) and associated valvular
affection in ﬁve cases.Fig. 1 4 Chamber (a) and short axis (b) IR image showing subendoca
enhancement along the territory of the RCA.
Fig. 2 4 Chamber b-FFE (a) showing an aneurysm in the basal asp
image (b) shows small thrombi formed on the wall (small arrows) w
myocardial infarction complicated by aneurysm and thrombi.7. Non-ischemic cardiomyopathy
The group of non-ischemic cardiomyopathies included six sub-
types seen in 33 patients.
7.1. 1-Dilated cardiomyopathy
In seven cases of dilated cardiomyopathy all patients showed
global hypokinesia and impaired contractility of the dilated
LV with decreased ejection fraction of 33–42%. Four of the
patients (57%) showed linear midwall enhancement of the left
ventricle (Fig. 3), while three patients did not show any myocar-
dial enhancement. Three of the patients showedmarked tricuspid
and mitral regurge associated with dilatation of all chambers.
7.2. 2-Restrictive cardiomyopathy
We diagnosed six patients with restrictive cardiomyopathy of
which four (66.6%) showed linear circumferential subendocar-
dial enhancement not related to a coronary artery territory
with normal myocardial wall thickness. Two of the patients
were known to have hypereosinophilic syndrome while the restrdial enhancement along the territory of the LAD and transmural
ect of the free lateral wall of the LV (long arrow). 4 chamber IR
ith enhancement of the basal free lateral LV wall denoting old
Fig. 3 4 Chamber (a) and short axis (b) showing midwall linear enhancement within the dilated lateral free wall and inferior wall of the
LV in a case of dilated cardiomyopathy.
Fig. 4 4 Chamber (a) and short axis (b) IR sequences showing LV apical thrombus (arrow) with subendocardial circumferential
enhancement not related to a coronary artery territory indicating restrictive cardiomyopathy. Dilatation of both atria is also noted.
56 N.H. Behairy, S.M. Mansourwere idiopathic type. One case of hyperesosinophilic syndrome
showed apical thrombi within (Fig. 4). Both dilated atria were
present in all cases. Most of these patients were sent to differ-
entiate restrictive cardiomyopathy from constrictive pericardi-
tis as both of them show diastolic impairment. Normal
pericardial thickness and absent septal bouncing excluded
the possibility of constrictive pericarditis in our cases.
7.3. 3-Hypertrophic cardiomyopathy (HCM)
Asymmetrical hypertrophy of the myocardium was found in
seven cases of HCM mainly at the interventricular septum
and apical region. Wall thickening ranged from 15 to 28 mm.
Patchy bizarre midwall enhancement pattern was mainly seen
in ﬁve patients (71%) at the regions of most hypertrophy
(Fig. 5). Reduced LV cavity with rather adequate contractility
was seen. LV outﬂow tract obstruction by subvalvular aortic
stenosis was found in four cases.
7.4. 4-Arrythmogenic right ventricular dysplasia (ARVD)
Three patients were diagnosed as ARVD according to
McKenna’s classiﬁcation. In addition two patients (66.6%)showed uniform enhancement of the whole right ventricle
denoting ﬁbrous replacement of the right ventricle which ap-
peared dilated and thinned (Fig. 6). The third patient showed
fatty replacement of the RV with no evidence of ﬁbrosis.
7.5. 5-LV non-compaction
Three cases of non-compaction were diagnosed showing typi-
cal pattern of ventricular dilation and hypertrophic trabeculae
separated by deep ﬁssures in the LV and involving the RV
(Fig. 7) with evidence of delayed myocardial enhancement
involving the non-compacted part seen in one case.
7.6. 6-Speciﬁc cardiomyopathies
Three cases of Behcet’s disease were evaluated by CMR of
which; one (33.3%) showed subendocardial right ventricular
enhancement denoting endomyocardial ﬁbrosis. All patients
showed intracavitary thrombi.
Four cases of sarcoidosis were evaluated. One of them (25%)
showed patchy midwall enhancement reaching the epicardium
due to myocardial inﬁltration with granulomatous tissue. The
enhanced patches did not reach the subendocardium and are
Fig. 5 4 Chamber (a) and short axis (b) IR images showing marked asymmetrical thickening of the LV wall with patchy bizarre midwall
enhancement of the anteroseptal and lateral wall of the LV denoting hypertrophic cardiomyopathy.
Fig. 6 4 Chamber b-FFE MRI (a) shows markedly dilated right atrium and ventricle with moderate pericardial effusion (star) and short
axis IR image (b) showing dilated RV with complete enhancement of the RV wall (arrows).
Fig. 7 2 Chamber (a) and 4 chamber (b) B-FFE images of a case of non-compaction showing dilated LV with hypertrophied trabeculae
and deep ﬁssures with percentage of non-compaction/compcation reaching >3:1.
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myocardium (Fig. 8). Adequate contractility and normal wall
thickness were found excluding hypertrophic cardiomyopathy.8. Discussion
Delayed contrast enhanced cardiac magnetic resonance imag-
ing has traditionally been used for the evaluation of ischemicheart disease speciﬁcally, with respect to infarction and viabil-
ity assessment. However, it is increasingly being used in the
evaluation of non-ischemic cardiomyopathies (2).
Administration of Gadolinium results in uptake of the con-
trast agent into both normal and injured myocardium. In nor-
mal myocardium there will be early wash out of contrast. In
injured myocardium the wash out is very slow resulting in de-
layed enhancement after 10–15 min compared to the normal
myocardium (5).
Fig. 8 IR short axis image in a known sarcoid patient shows
multiple patchy midwall enhanced foci at the midwall of the LV
(arrows) with no evidence of wall thickening indicating cardiac
sarcoidosis.
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nary artery territory, in which the subendocardium was always
involved in all of our patients with ischemic cardiomyopathy.
Such ﬁndings were similar to those reported in previous studies
(5–7). Complications of myocardial infarction, such as aneu-
rysm and thrombus formation, were also assessed with CMR
imaging as reported in previous studies (6).
Linear midwall pattern of enhancement was seen in 57% of
our patients with dilated cardiomyopathy. This pattern was
agreeable with McCrohon et al. (8) who examined 63 patients
with dilated cardiomyopathy and unobstructed coronary arter-
ies. He reported that 28% demonstrated longitudinal or pat-
chy midwall enhancement not reaching the endocardium,
was unrelated to any coronary territory. However the percent-
age of myocardial enhancement found was not correlated to
our percentage, likely due to the small number of patients in
our study. This enhancement is explained by the presence of
ﬁbrosis and indicates a poor prognosis. Patients with midmyo-
cardial enhancement are at higher risk of sudden cardiac death
and arrhythmias (9). That is why it is important to differentiate
between idiopathic dilated cardiomyopathy and ischemic di-
lated cardiomyopathy, as ischemic cardiomyopathy can be
treated with revascularization unlike idiopathic diseases which
have no speciﬁc treatment.
Patients diagnosed as restrictive cardiomyopathy showed
delayed myocardial enhancement over the entire subendocar-
dial circumference similar to those reported by Vogelsberg
et al. and Petros Nihoyannopoulos (10,11). In cases of hype-
reosinophilic syndrome there is eosinophil-mediated damage
of the subendocardium causing necrosis, thrombosis, and sub-
sequent late-stage ﬁbrosis of the endomyocardial surface of the
ventricles (12). The pattern of enhancement which is not re-
lated to a coronary artery territory; usually affecting the whole
LV circumference can differentiate the apical thrombus caused
by restrictive cardiomyopathy from those caused from myo-
cardial ischemia.
Both restrictive cardiomyopathy and constrictive pericardi-
tis are characterized by diastolic dysfunction and impairment
of ventricular ﬁlling with different management of each disease(13). The pattern of delayed myocardial enhancement in addi-
tion to the evaluation of pericardial thickening and septal
bouncing can differentiate between them.
HCM can be diagnosed on basis of having an abnormal
asymmetrical myocardial thickening. Knowing the fact that
the presence of delayed enhancement in HCM patients is asso-
ciated with increasing risk of sudden cardiac death, systolic
dysfunction and non-sustained ventricular tachycardia, makes
it very important to quantify and assess its presence.
Our study showed delayed myocardial enhancement pat-
tern in 71% of our HCM patients that characteristically ap-
pears as patchy bizarre shaped mid-wall enhancement.
Although, we could not rely on the percentage of affection
in HCM patients due to the limited number of cases, this pat-
tern is agreeable to previous studies (14).
According to Maron et al. and Davies (15,16) delayed myo-
cardial enhancement was most commonly located in both the
ventricular septum and LV free wall as detected in our cases
of HCM.
The standard of reference for the diagnosis of ARVD is
based on histologic demonstration of transmural ﬁbrofatty
replacement of right ventricular myocardium at either autopsy
or surgery. The use of endomyocardial biopsy to conﬁrm the
diagnosis is not recommended, especially since the right ven-
tricular wall is very thin and biopsy of this region risks perfo-
ration and cardiac tamponade (17).
Tandri et al. (18) reported the use of delayed-enhancement
CMR after the intravenous administration of gadolinium to
detect ARVD. He reported that 8/12 patients who met task
force criteria for ARVD demonstrated delayed enhancement
in the right ventricle. Such ﬁndings were also seen in our study;
two of our patients showed uniform enhancement of the di-
lated, thinned RV wall denoting ﬁbrous replacement, while
the third case showed only fatty replacement with no evidence
of ﬁbrosis.
Ventricular non-compaction is an extremely rare congenital
disorder of the left, right or both ventricles with high morbid-
ity and mortality due to heart failure, ventricular arrhythmias,
and systemic embolization. Grothoff et al. stated that none of
his patients with non-compaction demonstrated delayed myo-
cardial enhancement (19). However, other studies documented
the presence of delayed myocardial enhancement and that the
amount of delayed trabecular hyperenhancement correlates
signiﬁcantly with LV ejection fraction (LVEF) and is an inde-
pendent predictor of LVEF (20,21). We performed delayed
enhancement in our cases; one of them showed enhancement
of the whole RV wall. This is further documented by Chin
et al. (22) who found histological evidence of increased suben-
docardial ﬁbrosis within the areas of non-compacted myocar-
dium in his study.
According to Vignaux (23) late-enhancement areas in sar-
coidosis seem to have speciﬁc locations (basal interventricular
septum, lateral LV wall) and distribution patterns (patchy or
with striae that do not involve the subendocardium; diffuse
and transmural if the disease is advanced), which is agreeable
to our two cases of sarcoidosis. Since cardiac sarcoidosis is a
poor prognostic indicator, this pattern can help in the differen-
tiation between cardiac sarcoidosis and postischemic myocar-
dial injury and in planning their management.
Despite the rarity of cardiac involvement in Behcet’s dis-
ease, subendocardial ﬁbrosis of the right ventricle is considered
Table 2 Patterns of delayed enhancement reported in previous literature and in this study.
Types of
cardiomyopathies
Typical pattern of delayed enhancement
reported in the literature
Pattern of delayed enhancement
in our study
Ischemic cardiomyopathy Subendocardial, transmural LV, Subendocardial up to
transmural





Subendocardial LV, Subendocardial not related
to a coronary artery
Hypertrophic
cardiomyopathy




RV wall In the RV wall
LV non-compaction None, at the trabeculated part In areas of non-compaction LV
and/or RV
Behcet’s disease Subendocardial in the RV RV subendocardial
Sarcoidosis Mid-wall, subepicardial, ischemic-like LV, Patchy, mid and epicardial
LV = left ventricle, RV = right ventricle.
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mation (24), as was the case in our study.
Categorization of abnormal delayed myocardial enhance-
ment according to location (subendocardial, transmural, or
mesocardial) allows differentiation between ischemic (infarct-
related) and non-ischemic cardiomyopathies and, in cases of
non-ischemic cardiomyopathy, narrowing of the differential
diagnosis (Table 2). In combination with a high degree of clin-
ical suspicion, delayed contrast-enhanced cardiac MR imaging
can play a role in the early detection and appropriate treat-
ment of non-ischemic cardiomyopathies (2).
In pediatric patients or those patients with signiﬁcant
comorbidities, speciﬁc enhancement patterns on delayed con-
trast-enhanced cardiac MR images may obviate tissue sam-
pling altogether when concordant with a clinically suspected
diagnosis (10).
The use of delayed myocardial enhancement in addition to
other CMR functional images is a key to diagnose different
types of cardiomyopathies depending on the pattern of
enhancement. Moreover, quantiﬁcation of myocardial
enhancement including the site, extent and percentage of myo-
cardial involvement is highly important as a prognostic factor
in different cardiomyopathies. In ischemic cardiomyopathy,
the transmural extent of delayed myocardial enhancement is
a predictive of myocardial wall recovery after revasculariza-
tion, and also a predictive of adverse LV remodeling (25). At
the clinical level, infarct size is an independent prognostic fac-
tor for heart failure, arrhythmic events, and cardiac mortality
(26).
In non-ischemic dilated cardiomyopathy, Assomull et al.
(9) showed that the presence of delayed myocardial enhance-
ment was associated with a 3-fold increase of hospitalization
for heart failure or cardiac death and a 5-fold increase of sud-
den cardiac death or ventricular arrhythmias.
In HCM patients myocardial ﬁbrosis is probably the sub-
strate for premature death from heart failure and a risk factor
for primary ventricular arrhythmia in older patients, while
younger patients who die suddenly seem to have severe disar-
ray with only mild hypertrophy and ﬁbrosis (27). In another
study, the extent of hyperenhancement assessed by gadolinium
contrast enhanced MRI was linked with progressive diseaseand markers of clinical risk for sudden death in patients with
HCM (28).
We recommend the use of CMRI with delayed myocardial
enhancement in all types of cardiomyopathies, even those with
solid diagnosis based on clinical and echocardiographic ﬁnd-
ings to differentiate the types of cardiomyopathy and more
over to quantify myocardial ﬁbrosis since it is an important
prognostic factor.Conﬂict of interest
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